Tuberous Sclerosis Due to Deletion of Exons 4-8 in TSC2 Gene, Favourably Responding to Phenytoin and Everolimus: A Case Report

TSC2基因第4-8外显子缺失所致结节性硬化症,对苯妥英钠和依维莫司治疗反应良好:病例报告

阅读:1

Abstract

A case of tuberous sclerosis (TSC) caused by a previously unreported mutation, with epilepsy responding well to phenytoin (PHT) and multilocular benign tumors regressing with everolimus, has not been documented before, to the best of our knowledge. The patient is a 24-year-old female who was diagnosed with tuberous sclerosis complex (TSC) at the age of seven due to epilepsy and the presence of multiple hamartomas, including angiofibromas, angiomyolipomas, lymphangioleiomyomas, rhabdomyomas, and astrocytomas, throughout her body. She also has a history of developmental delay, mild cognitive impairment, adjustment disorder, claustrophobia, recurrent depressive episodes, anxiety disorder, and autism spectrum disorder. Genetic testing confirmed a deletion of exons 4-8 in the TSC2 gene. At the age of 10, monotherapy with PHT was started, which had such a favorable effect that no more seizures occurred until the age of 19. From the age of 19, she also received everolimus, as a result of which the multi-organ hamartomas regressed significantly. This case shows that epilepsy in TSC is not intractable, that phenytoin could be an option for epilepsy in TSC patients, and that everolimus is very effective in terms of regression of benign tumors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。